fluorouracil has been researched along with Hand-Foot Syndrome in 86 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Hand-Foot Syndrome: Chemotherapy-induced dermal side effects that are associated with the use of various CYTOSTATIC AGENTS. Symptoms range from mild ERYTHEMA and/or PARESTHESIA to severe ulcerative dermatitis with debilitating pain involving typically palmoplantar and intertriginous areas. These cutaneous manifestations are sometimes accompanied by nail anomalies.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Soaking affected hands or feet in a novel soaking solution safely and effectively reduced the severity of HFS following treatment with capecitabine for breast cancer." | 9.51 | Effect of a Novel Soaking Solution Used in Patients With Hand-Foot Syndrome as a Result of Capecitabine Treatment: A Randomized and Self-Controlled Trial. ( Chang, H; Chen, R; Cheng, J; Hu, T; Peng, X; Wang, J; Wang, Q; Xie, Y, 2022) |
| "This study is expected to contribute to the establishment of new supportive care for preventing HFS, not only for colorectal cancer patients receiving adjuvant chemotherapy, but also for various cancer patients receiving capecitabine-based chemotherapy." | 9.51 | Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC s ( Ahiko, Y; Aikou, S; Boku, N; Furukawa, N; Iimura, Y; Ishibashi, M; Kuroda, S; Nojima, M; Shida, D; Tanabe, T, 2022) |
| "A structured teaching module including intensive prophylactic measures to alleviate hand-foot syndrome (HFS) during capecitabine therapy is feasible but ineffective at protecting patients from HFS." | 9.34 | Effect of a Structured Teaching Module Including Intensive Prophylactic Measures on Reducing the Incidence of Capecitabine-Induced Hand-Foot Syndrome: Results of a Prospective Randomized Phase III Study. ( Chavan, N; Desouza, A; Gupta, S; Gupta, T; Kapoor, A; Mandavkar, S; Mirani, J; Murugan, K; Nashikkar, C; Ostwal, V; Ramaswamy, A; Saklani, A, 2020) |
| " This study was to evaluate the efficacy and safety of maintenance therapy with capecitabine versus observation following inductive chemotherapy in patients with metastatic colorectal cancer." | 9.22 | Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. ( Hu, XH; Jia, J; Li, YH; Lin, DR; Lin, YC; Luo, HY; Ma, D; Peng, JW; Wang, FH; Wang, W; Wang, ZQ; Xu, RH; Yuan, X; Zhang, DS, 2016) |
| "Patients with GI tumors or breast cancer treated with capecitabine were included in this randomized phase III study." | 9.20 | Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group. ( Al-Batran, SE; Bolz, G; Gencer, D; Hegewisch-Becker, S; Hofheinz, RD; Kronawitter, U; Loeffler, LM; Potenberg, J; Schneeweiss, A; Schulz, H; Stahl, M; Tauchert, F, 2015) |
| "The approved capecitabine regimen as monotherapy in metastatic breast cancer (MBC) is 1,250 mg/m(2) twice daily for 2 weeks on and 1 week off (Cint)." | 9.20 | Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis. ( Alonso, R; Caballero, R; Calvo, L; Caronia, D; Carrasco, E; Casado, A; Chacón, JI; Constenla, M; De la Haba, J; De la Torre-Montero, JC; García-Sáenz, JÁ; González-Neira, A; Guerra, E; Heras, L; Hernando, B; Jimeno, MÁ; Lluch, A; Martín, M; Martínez, N; Muñoz, M; Pita, G; Ramos, M; Ruíz-Borrego, M; Zamora, P, 2015) |
| "Adverse events associated with 5-fluorouracil (5FU) based adjuvant therapy in colorectal cancer (CRC) patients may predict survival." | 9.19 | Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? ( André, T; Bono, P; de Gramont, A; Hermunen, K; Österlund, P; Poussa, T; Quinaux, E; Soveri, LM, 2014) |
| "BACKGROUND/Aims: To determine the effect of the pyridoxine for prevention of hand-foot syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine." | 9.19 | The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study. ( Endo, I; Ichikawa, Y; Kunisaki, C; Osada, S; Ota, M; Shoichi, F; Suwa, H; Tanaka, K; Tatsumi, K; Watanabe, J; Watanabe, K, 2014) |
| "This study showed reproducible anticancer activity and tolerable toxicity of gemcitabine and capecitabine combination therapy in recurrent or metastatic Korean breast cancer patients previously treated with anthracycline and taxane." | 9.19 | Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. ( Ahn, JB; Chon, HJ; Chung, HC; Hong, MH; Jeung, HC; Kang, B; Lim, S; Nam, CM; Park, JS; Rha, SY; Yang, WI, 2014) |
| "Combinations of trastuzumab with paclitaxel or capecitabine are effective therapies in human epidermal growth factor 2 (HER2)-positive metastatic breast cancer (MBC)." | 9.17 | Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer. ( Benekli, M; Berk, V; Buyukberber, S; Coskun, U; Demirci, U; Ozkan, M; Sevinc, A; Tonyali, O; Ucgul, E; Uncu, D; Yildiz, R, 2013) |
| "Capecitabine/taxane combinations are highly active in metastatic breast cancer (MBC)." | 9.17 | Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. ( Beckmann, M; Du Bois, A; Eidtmann, H; Heilmann, V; Hubalek, M; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Richter, B; Schrader, I; Schuster, T; Stähler, A; Stickeler, E; Thomssen, C; Untch, M; von Minckwitz, G; Wollschläger, K, 2013) |
| "To evaluate the efficacy and safety of docetaxel plus capecitabine (DC) combination as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC)." | 9.16 | A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. ( Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N, 2012) |
| "Hand-foot syndrome (HFS) is a limiting toxicity of capecitabine, which is not life-threatening but could compromise capecitabine efficacy." | 9.16 | Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. ( Aparicio, J; Dueñas, R; Falcó, E; Gómez-Martin, C; Irigoyen, A; Lacasta, A; Llorente, B; López, RL; Muñoz, ML; Pérez, B; Reboredo, M; Regueiro, P; Safont, MJ; Sánchez, A; Sanchez-Viñes, E; Serrano, R, 2012) |
| "We performed an analysis of the efficacy of capecitabine monotherapy as maintenance treatment for metastatic breast cancer (MBC) after response to capecitabine-based chemotherapy [capecitabine plus docetaxel (XT) or vinorelbine (XN)] as a first-line or a second-line treatment." | 9.16 | Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer. ( Bian, L; Cao, Y; Huang, H; Jiang, Z; Song, S; Wang, T; Wu, S; Zhang, S, 2012) |
| "Hand-foot syndrome (HFS) is the most common adverse event induced by capecitabine." | 9.16 | Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. ( Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX, 2012) |
| "Oral administration of cyclophosphamide (CTX) and capecitabine may have a greater potential for treatment of metastatic breast cancer (MBC) due to anti-angiogenesis resulting from the metronomic dosage and upregulation of thymidine phosphorylase by CTX." | 9.16 | An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study. ( Hong, X; Hu, X; Leaw, S; Lu, J; Shao, Z; Wang, J; Wang, Z, 2012) |
| "5-Fluorouracil (5-Fu) is one of the most commonly prescribed antineoplastic agents against gastric and colorectal cancers." | 8.98 | Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis. ( Meng, F; Wang, Y; Xing, X; Zhang, L; Zhong, D, 2018) |
| "A 61-year-old woman with metastatic breast cancer who was undergoing treatment with capecitabine developed erythema, fissuring, and erosions over both hands and feet, consistent with HFS." | 8.87 | Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature. ( Baker, SG; Cotliar, JA; Gunawardane, ND; Hoesly, FJ, 2011) |
| "Hand-foot syndrome (HFS) is a serious dose-limiting cutaneous toxicity of capecitabine-containing chemotherapy, leading to a deteriorated quality of life and negative impacts on chemotherapy treatment." | 8.31 | Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil. ( Chen, Y; Hu, J; Luo, S; Lv, D; Wu, Z; Xie, X; Yang, B; Zhang, S, 2023) |
| "Occurrence of hand-foot syndrome (HFS) during capecitabine treatment often results in treatment interruptions (26 %) or treatment discontinuation (17 %), and can severely decrease quality of life." | 8.31 | Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD. ( Bins, S; de With, M; El Bouazzaoui, S; Homs, MYV; Maasland, DC; Mathijssen, RHJ; Mostert, B; Mulder, TAM; Oomen-de Hoop, E; van Doorn, L; van Schaik, RHN, 2023) |
| "S-1 is a valid alternative to capecitabine in case HFS or cardiotoxicity occurs." | 8.12 | Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer. ( Kwakman, JJM; Mol, L; Punt, CJA, 2022) |
| "Cancer patients treated with capecitabine and oxaliplatin (XELOX) often develop hand-foot syndrome (HFS) or palmar-plantar erythrodysesthesia." | 8.12 | Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. ( Al-Tassan, NA; Cheadle, JP; Escott-Price, V; Houlston, RS; Kaplan, R; Kerr, DJ; Kerr, R; Madi, A; Maughan, TS; Palles, C; Watts, K; Wills, C, 2022) |
| " We reported an advanced lung adenocarcinoma female patient, who developed a Grade 3 HFS after a third-line treatment with apatinib of 250 mg for 10 days, the patient developed intolerable pain with pruritus." | 7.96 | Apatinib-induced Grade 3 hand-foot syndrome in advanced lung adenocarcinoma successful treated with thalidomide: A case report. ( Du, LY; Jia, YM; Lei, KJ; Li, T; Qiu, Y; Ren, Y; Wang, SB, 2020) |
| "Hand-foot syndrome (HFS) is the most frequently reported side effect of oral capecitabine therapy." | 7.80 | Topical henna ameliorated capecitabine-induced hand-foot syndrome. ( Ilyas, S; Saif, MW; Wasif, K, 2014) |
| "Capecitabine is one of the most effective oral chemotherapeutic drugs for advanced or recurrent colorectal cancer and gastric cancer." | 7.79 | [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy]. ( Amemori, K; Koike, C; Shigematsu, T; Shirai, M; Sunda, K; Takeda, K; Yamada, T; Yamagiwa, K, 2013) |
| "Hand-foot syndrome( HFS) has been reported to be the most common adverse effect of capecitabine, with an incidence of more than 50%." | 7.79 | [Efficacy of AboundTM for hand-foot syndrome caused by capecitabine]. ( Fujii, C; Fujino, M; Fukunaga, M; Hachino, Y; Hamaguchi, Y; Imamura, H; Iseki, C; Ishizaka, T; Kamigaki, S; Kawabata, R; Kawase, T; Kimura, Y; Yamamoto, E, 2013) |
| "Capecitabine, an oral prodrug of 5-fluorouracil (5-FU), is a promising treatment for colorectal, breast and gastric cancers, but often causes hand-foot syndrome (HFS), the most common dose-limiting toxicity." | 7.78 | Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer. ( Azuma, Y; Fujiwara, Y; Hata, K; Hirakawa, A; Makino, Y; Morikawa, N; Ryushima, Y; Sai, K; Saito, Y; Tohkin, M; Udagawa, R; Yamamoto, H; Yokote, N, 2012) |
| "Three hundred and seventy-six patients with advanced breast cancer were treated with capecitabine-based chemotherapy regimens in our department from Sep 2002 to Sep 2009." | 7.77 | [Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer]. ( Bian, L; Cao, Y; Huang, HY; Jiang, ZF; Song, ST; Wang, T; Wu, SK; Zhang, SH, 2011) |
| "Soaking affected hands or feet in a novel soaking solution safely and effectively reduced the severity of HFS following treatment with capecitabine for breast cancer." | 5.51 | Effect of a Novel Soaking Solution Used in Patients With Hand-Foot Syndrome as a Result of Capecitabine Treatment: A Randomized and Self-Controlled Trial. ( Chang, H; Chen, R; Cheng, J; Hu, T; Peng, X; Wang, J; Wang, Q; Xie, Y, 2022) |
| "This study is expected to contribute to the establishment of new supportive care for preventing HFS, not only for colorectal cancer patients receiving adjuvant chemotherapy, but also for various cancer patients receiving capecitabine-based chemotherapy." | 5.51 | Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC s ( Ahiko, Y; Aikou, S; Boku, N; Furukawa, N; Iimura, Y; Ishibashi, M; Kuroda, S; Nojima, M; Shida, D; Tanabe, T, 2022) |
| " However, hand-foot syndrome (HFS) has high incidence, and once developed, the symptoms significantly impair quality of life (QOL), leading to a reduction in the dosage or discontinuation of the treatment." | 5.43 | Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer. ( Achrekar, MS; Carvalho, MD; D'souza, A; Govindarajan, S; Gupta, S; Murugan, K; Ostwal, V, 2016) |
| "Capecitabine was discontinued 287 days after initiation owing to exacerbation of the hand-foot syndrome." | 5.42 | [A case of lacrimal duct obstruction caused by capecitabine]. ( Kawara, H; Mitani, T; Noguchi, Y; Shimizu, Y; Tamura, Y; Tokuyama, Y; Uchiyama, K, 2015) |
| "A primary challenge in identifying replicable pharmacogenomic markers from clinical genomewide association study (GWAS) trials in oncology is the difficulty in performing a second large clinical trial with the same drugs and dosage regimen." | 5.40 | Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses. ( Alba, E; Alonso, R; de la Torre-Montero, JC; Dolan, ME; González-Neira, A; Lopez-Fernandez, LA; Martín, M; Pita, G; Wheeler, HE, 2014) |
| "Capecitabine was administered orally for 14 days of each 21-day cycle." | 5.40 | Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance study. ( Fuxius, S; Hahn, LJ; Hurst, U; Lerchenmüller, C; Luhn, B; Müller, V; Soeling, U; Steffens, CC; Vehling-Kaiser, U; Wohlfarth, T; Zaiss, M, 2014) |
| "A structured teaching module including intensive prophylactic measures to alleviate hand-foot syndrome (HFS) during capecitabine therapy is feasible but ineffective at protecting patients from HFS." | 5.34 | Effect of a Structured Teaching Module Including Intensive Prophylactic Measures on Reducing the Incidence of Capecitabine-Induced Hand-Foot Syndrome: Results of a Prospective Randomized Phase III Study. ( Chavan, N; Desouza, A; Gupta, S; Gupta, T; Kapoor, A; Mandavkar, S; Mirani, J; Murugan, K; Nashikkar, C; Ostwal, V; Ramaswamy, A; Saklani, A, 2020) |
| " This study was to evaluate the efficacy and safety of maintenance therapy with capecitabine versus observation following inductive chemotherapy in patients with metastatic colorectal cancer." | 5.22 | Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. ( Hu, XH; Jia, J; Li, YH; Lin, DR; Lin, YC; Luo, HY; Ma, D; Peng, JW; Wang, FH; Wang, W; Wang, ZQ; Xu, RH; Yuan, X; Zhang, DS, 2016) |
| "Capecitabine is a common drug in the therapy against metastatic breast cancer due to its manageable safety profile." | 5.22 | Capecitabine induced fingerprint loss: Case report and review of the literature. ( Cherem-Kibrit, M; Colmenero-Mercado, JO; Deneken-Hernandez, Z; Gutiérrez-Andrade, L; Rodríguez-Gutiérrez, G, 2022) |
| "The approved capecitabine regimen as monotherapy in metastatic breast cancer (MBC) is 1,250 mg/m(2) twice daily for 2 weeks on and 1 week off (Cint)." | 5.20 | Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis. ( Alonso, R; Caballero, R; Calvo, L; Caronia, D; Carrasco, E; Casado, A; Chacón, JI; Constenla, M; De la Haba, J; De la Torre-Montero, JC; García-Sáenz, JÁ; González-Neira, A; Guerra, E; Heras, L; Hernando, B; Jimeno, MÁ; Lluch, A; Martín, M; Martínez, N; Muñoz, M; Pita, G; Ramos, M; Ruíz-Borrego, M; Zamora, P, 2015) |
| "Patients with GI tumors or breast cancer treated with capecitabine were included in this randomized phase III study." | 5.20 | Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group. ( Al-Batran, SE; Bolz, G; Gencer, D; Hegewisch-Becker, S; Hofheinz, RD; Kronawitter, U; Loeffler, LM; Potenberg, J; Schneeweiss, A; Schulz, H; Stahl, M; Tauchert, F, 2015) |
| "This study showed reproducible anticancer activity and tolerable toxicity of gemcitabine and capecitabine combination therapy in recurrent or metastatic Korean breast cancer patients previously treated with anthracycline and taxane." | 5.19 | Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. ( Ahn, JB; Chon, HJ; Chung, HC; Hong, MH; Jeung, HC; Kang, B; Lim, S; Nam, CM; Park, JS; Rha, SY; Yang, WI, 2014) |
| "Adverse events associated with 5-fluorouracil (5FU) based adjuvant therapy in colorectal cancer (CRC) patients may predict survival." | 5.19 | Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? ( André, T; Bono, P; de Gramont, A; Hermunen, K; Österlund, P; Poussa, T; Quinaux, E; Soveri, LM, 2014) |
| "To observe the effect of the Traditional Chinese Medicine, modified Taohongsiwu decoction, versus pyridoxine on patients with hand-foot syndrome (HFS) from capecitabine, sorafenib, and gefitinib chemotherapy for gastric, lung, breast, colon, or rectal cancer." | 5.19 | Effect of modified taohongsiwu decoction on patients with chemotherapy-induced hand-foot syndrome. ( Chen, J; Chen, X; Dai, C; Wu, X; Yu, B; Zhao, C; Zhou, C, 2014) |
| "BACKGROUND/Aims: To determine the effect of the pyridoxine for prevention of hand-foot syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine." | 5.19 | The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study. ( Endo, I; Ichikawa, Y; Kunisaki, C; Osada, S; Ota, M; Shoichi, F; Suwa, H; Tanaka, K; Tatsumi, K; Watanabe, J; Watanabe, K, 2014) |
| "Capecitabine is used mainly with oxaliplatin to treat metastatic colorectal cancer (mCRC)." | 5.19 | A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study). ( Goto, A; Hamamoto, Y; Morita, S; Nakajima, T; Nakayama, N; Nishina, T; Sakamoto, J; Shimada, K; Ura, T; Yamada, Y; Yamaguchi, T; Yamazaki, K, 2014) |
| "Combinations of trastuzumab with paclitaxel or capecitabine are effective therapies in human epidermal growth factor 2 (HER2)-positive metastatic breast cancer (MBC)." | 5.17 | Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer. ( Benekli, M; Berk, V; Buyukberber, S; Coskun, U; Demirci, U; Ozkan, M; Sevinc, A; Tonyali, O; Ucgul, E; Uncu, D; Yildiz, R, 2013) |
| "Capecitabine/taxane combinations are highly active in metastatic breast cancer (MBC)." | 5.17 | Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. ( Beckmann, M; Du Bois, A; Eidtmann, H; Heilmann, V; Hubalek, M; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Richter, B; Schrader, I; Schuster, T; Stähler, A; Stickeler, E; Thomssen, C; Untch, M; von Minckwitz, G; Wollschläger, K, 2013) |
| "We performed an analysis of the efficacy of capecitabine monotherapy as maintenance treatment for metastatic breast cancer (MBC) after response to capecitabine-based chemotherapy [capecitabine plus docetaxel (XT) or vinorelbine (XN)] as a first-line or a second-line treatment." | 5.16 | Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer. ( Bian, L; Cao, Y; Huang, H; Jiang, Z; Song, S; Wang, T; Wu, S; Zhang, S, 2012) |
| "To evaluate the efficacy and safety of docetaxel plus capecitabine (DC) combination as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC)." | 5.16 | A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. ( Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N, 2012) |
| "Hand-foot syndrome (HFS) is the most common adverse event induced by capecitabine." | 5.16 | Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. ( Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX, 2012) |
| "Oral administration of cyclophosphamide (CTX) and capecitabine may have a greater potential for treatment of metastatic breast cancer (MBC) due to anti-angiogenesis resulting from the metronomic dosage and upregulation of thymidine phosphorylase by CTX." | 5.16 | An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study. ( Hong, X; Hu, X; Leaw, S; Lu, J; Shao, Z; Wang, J; Wang, Z, 2012) |
| "A total of 106 patients planned for palliative single-agent capecitabine (53 in each arm, 65%/35% colorectal/breast cancer) were randomised to receive either concomitant pyridoxine (50 mg po) or matching placebo three times daily." | 5.16 | A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. ( Ahmad, A; Armstrong, G; Blesing, C; Bond, S; Bulusu, R; Corrie, PG; Daniel, F; Hardy, R; Hill, M; Lao-Sirieix, S; McAdam, K; Moody, AM; Osborne, M; Parashar, D; Wilson, CB; Wilson, G, 2012) |
| "Hand-foot syndrome (HFS) is a limiting toxicity of capecitabine, which is not life-threatening but could compromise capecitabine efficacy." | 5.16 | Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. ( Aparicio, J; Dueñas, R; Falcó, E; Gómez-Martin, C; Irigoyen, A; Lacasta, A; Llorente, B; López, RL; Muñoz, ML; Pérez, B; Reboredo, M; Regueiro, P; Safont, MJ; Sánchez, A; Sanchez-Viñes, E; Serrano, R, 2012) |
| "5-Fluorouracil (5-Fu) is one of the most commonly prescribed antineoplastic agents against gastric and colorectal cancers." | 4.98 | Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis. ( Meng, F; Wang, Y; Xing, X; Zhang, L; Zhong, D, 2018) |
| "A 61-year-old woman with metastatic breast cancer who was undergoing treatment with capecitabine developed erythema, fissuring, and erosions over both hands and feet, consistent with HFS." | 4.87 | Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature. ( Baker, SG; Cotliar, JA; Gunawardane, ND; Hoesly, FJ, 2011) |
| "Hand-foot syndrome (HFS) is a serious dose-limiting cutaneous toxicity of capecitabine-containing chemotherapy, leading to a deteriorated quality of life and negative impacts on chemotherapy treatment." | 4.31 | Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil. ( Chen, Y; Hu, J; Luo, S; Lv, D; Wu, Z; Xie, X; Yang, B; Zhang, S, 2023) |
| "Occurrence of hand-foot syndrome (HFS) during capecitabine treatment often results in treatment interruptions (26 %) or treatment discontinuation (17 %), and can severely decrease quality of life." | 4.31 | Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD. ( Bins, S; de With, M; El Bouazzaoui, S; Homs, MYV; Maasland, DC; Mathijssen, RHJ; Mostert, B; Mulder, TAM; Oomen-de Hoop, E; van Doorn, L; van Schaik, RHN, 2023) |
| " The use of the oral FP S-1 has been approved by the European Medicines Agency as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic CRC in whom it is not possible to continue treatment with another FP due to hand-foot syndrome (HFS) or cardiovascular toxicity (CVT)." | 4.31 | Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer. ( André, T; Bodoky, G; Cremolini, C; Heinemann, V; Maughan, T; McDermott, R; Osterlund, P; Pfeiffer, P; Punt, CJA; Teske, AJ; Van Cutsem, E, 2023) |
| "Cancer patients treated with capecitabine and oxaliplatin (XELOX) often develop hand-foot syndrome (HFS) or palmar-plantar erythrodysesthesia." | 4.12 | Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. ( Al-Tassan, NA; Cheadle, JP; Escott-Price, V; Houlston, RS; Kaplan, R; Kerr, DJ; Kerr, R; Madi, A; Maughan, TS; Palles, C; Watts, K; Wills, C, 2022) |
| " Female sex, breast cancer diagnosis, capecitabine monotherapy, and severe HFS were found to be associated with dose reductions (p-values < 0." | 4.12 | Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of patient-reported outcomes. ( Barton, DL; Chittiprolu, A; Cho, Y; Gong, Y; Harden, K; Harris, MR; Jiang, Y; Mason, M; Zhang, X, 2022) |
| "S-1 is a valid alternative to capecitabine in case HFS or cardiotoxicity occurs." | 4.12 | Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer. ( Kwakman, JJM; Mol, L; Punt, CJA, 2022) |
| " We reported an advanced lung adenocarcinoma female patient, who developed a Grade 3 HFS after a third-line treatment with apatinib of 250 mg for 10 days, the patient developed intolerable pain with pruritus." | 3.96 | Apatinib-induced Grade 3 hand-foot syndrome in advanced lung adenocarcinoma successful treated with thalidomide: A case report. ( Du, LY; Jia, YM; Lei, KJ; Li, T; Qiu, Y; Ren, Y; Wang, SB, 2020) |
| "Hand-foot syndrome (HFS) is the most frequently reported side effect of oral capecitabine therapy." | 3.80 | Topical henna ameliorated capecitabine-induced hand-foot syndrome. ( Ilyas, S; Saif, MW; Wasif, K, 2014) |
| "Capecitabine is one of the most effective oral chemotherapeutic drugs for advanced or recurrent colorectal cancer and gastric cancer." | 3.79 | [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy]. ( Amemori, K; Koike, C; Shigematsu, T; Shirai, M; Sunda, K; Takeda, K; Yamada, T; Yamagiwa, K, 2013) |
| "Hand-foot syndrome( HFS) has been reported to be the most common adverse effect of capecitabine, with an incidence of more than 50%." | 3.79 | [Efficacy of AboundTM for hand-foot syndrome caused by capecitabine]. ( Fujii, C; Fujino, M; Fukunaga, M; Hachino, Y; Hamaguchi, Y; Imamura, H; Iseki, C; Ishizaka, T; Kamigaki, S; Kawabata, R; Kawase, T; Kimura, Y; Yamamoto, E, 2013) |
| "Capecitabine, an oral prodrug of 5-fluorouracil (5-FU), is a promising treatment for colorectal, breast and gastric cancers, but often causes hand-foot syndrome (HFS), the most common dose-limiting toxicity." | 3.78 | Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer. ( Azuma, Y; Fujiwara, Y; Hata, K; Hirakawa, A; Makino, Y; Morikawa, N; Ryushima, Y; Sai, K; Saito, Y; Tohkin, M; Udagawa, R; Yamamoto, H; Yokote, N, 2012) |
| "Capecitabine, an oral prodrug of 5 -fluorouracil, is a promising treatment for colorectal, breast, and gastric cancers, but often causes hand-foot syndrome(HFS), which is the most common dose-limiting toxicity." | 3.78 | [Assessment of hand-foot syndrome in cancer outpatients undergoing chemotherapy]. ( Amamori, K; Shigematsu, T; Shirai, M; Sunda, K; Takeda, K; Yamagiwa, K; Yamanda, T, 2012) |
| ", drug-adverse event pairs, found in 1,644,220 AERs from 2004 to 2009, it was suggested that leukopenia, neutropenia, and thrombocytopenia were more frequently accompanied by the use of 5-FU than capecitabine, whereas diarrhea, nausea, vomiting, and hand-foot syndrome were more frequently associated with capecitabine." | 3.78 | Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. ( Brown, JB; Kadoyama, K; Miki, I; Okuno, Y; Sakaeda, T; Tamura, T, 2012) |
| "Regarding patients being treated for breast cancer and on oral capecitabine, the main side effect is the hand-foot syndrome (HFS), or Palmar-Plantar Erythrodysesthesia (PPE)." | 3.78 | [Breast cancer and the hand-foot syndrome]. ( Carrié, S; Cottu, P; De Rycke, Y; Falcou, MC; Llambrich, C; Medjbari, M, 2012) |
| "Three hundred and seventy-six patients with advanced breast cancer were treated with capecitabine-based chemotherapy regimens in our department from Sep 2002 to Sep 2009." | 3.77 | [Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer]. ( Bian, L; Cao, Y; Huang, HY; Jiang, ZF; Song, ST; Wang, T; Wu, SK; Zhang, SH, 2011) |
| " It was motivated by an attempt to develop a model-based dose adaptation tool for clinical use in colorectal cancer patients receiving capecitabine, which induces severe hand-and-foot syndrome (HFS) toxicity in more than a half of the patients." | 3.77 | Empirical Bayes estimation of random effects of a mixed-effects proportional odds Markov model for ordinal data. ( Girard, P; Paule, I; Tod, M, 2011) |
| "Palmar-Plantar syndrome (PPS) is a common side effect of oral capecitabine--a chemotherapeutic agent used as an adjuvant treatment for colorectal cancer." | 3.76 | Observations and hypothesis on an individual patient topically treated for capecitabine-induced Palmar-Plantar syndrome. ( Begent, R; Gafson, AR; Goodkin, O, 2010) |
| "The topical dosage form was standardized based on its Lawsone content." | 3.01 | Efficacy of topical ( Afshar, M; Jafariazar, Z; Mohajerani, R; Shahi, F, 2021) |
| "To evaluate the activity and tolerance of gemcitabine in combination with docetaxel and capecitabine in previously untreated patients with advanced pancreatic cancer." | 2.77 | Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study. ( Amarantidis, K; Chamalidou, E; Chelis, L; Chiotis, A; Courcoutsakis, N; Dimopoulos, P; Kakolyris, S; Prassopoulos, P; Tentes, A; Xenidis, N, 2012) |
| "Patients with advanced solid tumors (ECOG PS 0-1) were included." | 2.77 | A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine. ( Bendell, JC; Burris, HA; Greco, FA; Hainsworth, JD; Infante, JR; Jones, SF; Lane, CM; Spigel, DR; Yardley, DA, 2012) |
| "Oral capecitabine is an effective alternative to bolus 5-FU/FA as adjuvant treatment of patients with stage III colon cancer with efficacy benefits maintained at 5 years and in older patients." | 2.77 | Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. ( Cassidy, J; Díaz-Rubio, E; Gilberg, F; McKendrick, J; Scheithauer, W; Seitz, JF; Twelves, C; Van Hazel, G; Wong, A, 2012) |
| " Most frequent drug-related adverse events were hand-foot skin reaction (HFSR, 89%), diarrhea (71%), and fatigue (69%)." | 2.76 | Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial. ( Awada, A; Besse-Hammer, T; Brendel, E; Delesen, H; Gil, T; Hendlisz, A; Joosten, MC; Lathia, CD; Loembé, BA; Piccart-Ghebart, M; Van Hamme, J; Whenham, N, 2011) |
| "According to the Trastuzumab for Gastric Cancer (ToGA) study, trastuzumab plus cisplatin and capecitabine/5-fluorouracil (5-FU) is standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive advanced oesophagogastric cancer." | 2.58 | Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis. ( Creemers, A; de Waal, L; Ter Veer, E; van Laarhoven, HWM; van Oijen, MGH, 2018) |
| " However, hand-foot syndrome (HFS) has high incidence, and once developed, the symptoms significantly impair quality of life (QOL), leading to a reduction in the dosage or discontinuation of the treatment." | 1.43 | Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer. ( Achrekar, MS; Carvalho, MD; D'souza, A; Govindarajan, S; Gupta, S; Murugan, K; Ostwal, V, 2016) |
| "Thirteen patients with colon cancer and 7 patients with rectal cancer were enrolled after curative surgery." | 1.42 | [The present status of CapeOX as adjuvant chemotherapy for colorectal cancer]. ( Ishii, K; Kanamoto, A; Miyanaga, S; Noto, M; Takeda, T; Tani, T; Yagi, M, 2015) |
| "Capecitabine was discontinued 287 days after initiation owing to exacerbation of the hand-foot syndrome." | 1.42 | [A case of lacrimal duct obstruction caused by capecitabine]. ( Kawara, H; Mitani, T; Noguchi, Y; Shimizu, Y; Tamura, Y; Tokuyama, Y; Uchiyama, K, 2015) |
| "A primary challenge in identifying replicable pharmacogenomic markers from clinical genomewide association study (GWAS) trials in oncology is the difficulty in performing a second large clinical trial with the same drugs and dosage regimen." | 1.40 | Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses. ( Alba, E; Alonso, R; de la Torre-Montero, JC; Dolan, ME; González-Neira, A; Lopez-Fernandez, LA; Martín, M; Pita, G; Wheeler, HE, 2014) |
| "Capecitabine was administered orally for 14 days of each 21-day cycle." | 1.40 | Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance study. ( Fuxius, S; Hahn, LJ; Hurst, U; Lerchenmüller, C; Luhn, B; Müller, V; Soeling, U; Steffens, CC; Vehling-Kaiser, U; Wohlfarth, T; Zaiss, M, 2014) |
| "In phase II cancer trials, tumour response is either the primary or an important secondary endpoint." | 1.39 | Using continuous data on tumour measurements to improve inference in phase II cancer studies. ( Seaman, SR; Wason, JM, 2013) |
| " The most frequent adverse symptom of skin and subcutaneous toxicity reported in the patients treated with modified schedule of FOLFOX was pruritus (grade 1)." | 1.39 | Comparative assessment of skin and subcutaneous toxicity in patients of advanced colorectal carcinoma treated with different schedules of FOLFOX. ( Bano, N; Mateen, A; Najam, R, 2013) |
| "Because the gastric cancer was HER2-positive, she was treated with trastuzumab plus capecitabine plus cisplatin(XP)chemotherapy as third-line treatment." | 1.39 | [A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment]. ( Fuyuki, A; Hata, Y; Kanoshima, K; Kuriyama, H; Kuwabara, H; Matsuura, T; Murata, Y; Taniguchi, R; Tomeno, W; Uchiyama, T, 2013) |
| " However, many toxic effects are evaluated on a categorical scale." | 1.38 | Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation. ( Freyer, G; Girard, P; Hénin, E; Paule, I; Tod, M; You, B, 2012) |
| "Capecitabine(Xeloda®)has been a global standard drug for the treatment of colon cancer since large randomized controlled trials demonstrated its efficacy and safety in treating patients suffering from the disease." | 1.38 | [Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients]. ( Fukuda, M; Hanada, K; Hata, H; Ikai, I; Kubo, K; Moriyama, S; Murakami, T; Ogiso, S; Okazaki, S; Okuchi, Y; Otani, T; Sakata, S; Setoguchi, Y; Tanaka, M; Tani, M; Une, Y; Yamaguchi, T; Yamato, T; Yasui, H, 2012) |
| "Capecitabine is an orally administered pro-drug of 5-fluorouracil that confers superior disease-free survival and presumably has a more favourable side-effect profile." | 1.38 | Hypertriglyceridaemia-induced pancreatitis: a contributory role of capecitabine? ( Chan, AO; Chan, HY; Ng, CM; Shek, CC; Tiu, SC, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 72 (83.72) | 24.3611 |
| 2020's | 14 (16.28) | 2.80 |
| Authors | Studies |
|---|---|
| Deneken-Hernandez, Z | 1 |
| Cherem-Kibrit, M | 1 |
| Gutiérrez-Andrade, L | 1 |
| Rodríguez-Gutiérrez, G | 1 |
| Colmenero-Mercado, JO | 1 |
| Punt, CJA | 2 |
| Kwakman, JJM | 1 |
| Mol, L | 1 |
| Xie, Y | 1 |
| Wang, Q | 1 |
| Hu, T | 1 |
| Chen, R | 1 |
| Wang, J | 2 |
| Chang, H | 1 |
| Peng, X | 1 |
| Cheng, J | 1 |
| Watts, K | 1 |
| Wills, C | 1 |
| Madi, A | 1 |
| Palles, C | 2 |
| Maughan, TS | 1 |
| Kaplan, R | 1 |
| Al-Tassan, NA | 1 |
| Kerr, R | 1 |
| Kerr, DJ | 1 |
| Houlston, RS | 1 |
| Escott-Price, V | 1 |
| Cheadle, JP | 1 |
| Uppala, PK | 1 |
| Varghese, AM | 1 |
| Yella, SST | 1 |
| Velmurugan, H | 1 |
| Thangaraju, P | 1 |
| Krishna Sasanka, KSBS | 1 |
| Iimura, Y | 1 |
| Furukawa, N | 1 |
| Ishibashi, M | 1 |
| Ahiko, Y | 1 |
| Tanabe, T | 1 |
| Aikou, S | 1 |
| Shida, D | 1 |
| Nojima, M | 1 |
| Kuroda, S | 1 |
| Boku, N | 1 |
| Jiang, Y | 1 |
| Mason, M | 1 |
| Cho, Y | 1 |
| Chittiprolu, A | 1 |
| Zhang, X | 1 |
| Harden, K | 1 |
| Gong, Y | 1 |
| Harris, MR | 1 |
| Barton, DL | 1 |
| Yang, B | 1 |
| Xie, X | 1 |
| Lv, D | 1 |
| Hu, J | 1 |
| Chen, Y | 1 |
| Wu, Z | 1 |
| Luo, S | 1 |
| Zhang, S | 2 |
| de With, M | 1 |
| van Doorn, L | 2 |
| Maasland, DC | 1 |
| Mulder, TAM | 1 |
| Oomen-de Hoop, E | 1 |
| Mostert, B | 1 |
| Homs, MYV | 1 |
| El Bouazzaoui, S | 1 |
| Mathijssen, RHJ | 1 |
| van Schaik, RHN | 1 |
| Bins, S | 2 |
| Heinemann, V | 2 |
| Maughan, T | 1 |
| Cremolini, C | 1 |
| Van Cutsem, E | 2 |
| McDermott, R | 1 |
| Bodoky, G | 1 |
| André, T | 2 |
| Osterlund, P | 2 |
| Teske, AJ | 1 |
| Pfeiffer, P | 1 |
| Hamzic, S | 1 |
| Kummer, D | 1 |
| Froehlich, TK | 1 |
| Joerger, M | 1 |
| Aebi, S | 1 |
| Thomlinson, I | 1 |
| Meulendijks, D | 1 |
| Schellens, JHM | 1 |
| García-González, X | 1 |
| López-Fernández, LA | 2 |
| Amstutz, U | 1 |
| Largiadèr, CR | 1 |
| Ren, Y | 1 |
| Li, T | 1 |
| Du, LY | 1 |
| Qiu, Y | 1 |
| Wang, SB | 1 |
| Lei, KJ | 1 |
| Jia, YM | 1 |
| Ostwal, V | 2 |
| Kapoor, A | 1 |
| Mandavkar, S | 1 |
| Chavan, N | 1 |
| Gupta, T | 1 |
| Mirani, J | 1 |
| Saklani, A | 1 |
| Desouza, A | 1 |
| Murugan, K | 2 |
| Nashikkar, C | 1 |
| Gupta, S | 2 |
| Ramaswamy, A | 1 |
| Mohajerani, R | 1 |
| Shahi, F | 1 |
| Jafariazar, Z | 1 |
| Afshar, M | 1 |
| Matsuda, K | 1 |
| Namiki, T | 1 |
| Ueno, M | 1 |
| Hashimoto, T | 1 |
| Hanafusa, T | 1 |
| Yokozeki, H | 1 |
| Zhang, L | 1 |
| Xing, X | 1 |
| Meng, F | 1 |
| Wang, Y | 1 |
| Zhong, D | 1 |
| Dalenc, F | 1 |
| Ribet, V | 1 |
| Rossi, AB | 1 |
| Guyonnaud, J | 1 |
| Bernard-Marty, C | 1 |
| de Lafontan, B | 1 |
| Salas, S | 1 |
| Ranc Royo, AL | 1 |
| Sarda, C | 1 |
| Levasseur, N | 1 |
| Massabeau, C | 1 |
| Levecq, JM | 1 |
| Dulguerova, P | 1 |
| Guerrero, D | 1 |
| Sibaud, V | 1 |
| Chao, YL | 1 |
| Anders, CK | 1 |
| Ter Veer, E | 1 |
| Creemers, A | 1 |
| de Waal, L | 1 |
| van Oijen, MGH | 1 |
| van Laarhoven, HWM | 1 |
| Alcalde-Castro, J | 1 |
| Soto-Perez-de-Celis, E | 2 |
| Reyes-Gutiérrez, E | 1 |
| Orozco-Topete, R | 1 |
| León-Rodríguez, E | 1 |
| Chávarri-Guerra, Y | 2 |
| Hubner, RA | 1 |
| Worsnop, F | 1 |
| Cunningham, D | 1 |
| Chau, I | 1 |
| Tonyali, O | 1 |
| Benekli, M | 1 |
| Berk, V | 1 |
| Coskun, U | 1 |
| Ozkan, M | 1 |
| Yildiz, R | 1 |
| Ucgul, E | 1 |
| Sevinc, A | 1 |
| Uncu, D | 1 |
| Demirci, U | 1 |
| Buyukberber, S | 1 |
| Bano, N | 1 |
| Najam, R | 1 |
| Mateen, A | 1 |
| Lück, HJ | 1 |
| Du Bois, A | 1 |
| Loibl, S | 1 |
| Schrader, I | 1 |
| Huober, J | 1 |
| Heilmann, V | 1 |
| Beckmann, M | 1 |
| Stähler, A | 1 |
| Jackisch, C | 1 |
| Hubalek, M | 1 |
| Richter, B | 1 |
| Stickeler, E | 1 |
| Eidtmann, H | 1 |
| Thomssen, C | 1 |
| Untch, M | 1 |
| Wollschläger, K | 1 |
| Schuster, T | 1 |
| von Minckwitz, G | 1 |
| Wason, JM | 1 |
| Seaman, SR | 1 |
| Murata, Y | 1 |
| Matsuura, T | 1 |
| Kanoshima, K | 1 |
| Kuwabara, H | 1 |
| Fuyuki, A | 1 |
| Tomeno, W | 1 |
| Taniguchi, R | 1 |
| Uchiyama, T | 1 |
| Kuriyama, H | 1 |
| Hata, Y | 1 |
| Curigliano, G | 1 |
| Pivot, X | 1 |
| Cortés, J | 1 |
| Elias, A | 1 |
| Cesari, R | 1 |
| Khosravan, R | 1 |
| Collier, M | 1 |
| Huang, X | 1 |
| Cataruozolo, PE | 1 |
| Kern, KA | 1 |
| Goldhirsch, A | 1 |
| Ilyas, S | 1 |
| Wasif, K | 1 |
| Saif, MW | 1 |
| Hamaker, ME | 1 |
| Seynaeve, C | 1 |
| Wymenga, AN | 1 |
| van Tinteren, H | 1 |
| Nortier, JW | 1 |
| Maartense, E | 1 |
| de Graaf, H | 1 |
| de Jongh, FE | 1 |
| Braun, JJ | 1 |
| Los, M | 1 |
| Schrama, JG | 1 |
| van Leeuwen-Stok, AE | 1 |
| de Groot, SM | 1 |
| Smorenburg, CH | 1 |
| Fujii, C | 1 |
| Imamura, H | 1 |
| Fukunaga, M | 1 |
| Kamigaki, S | 1 |
| Kimura, Y | 1 |
| Kawase, T | 1 |
| Kawabata, R | 1 |
| Fujino, M | 1 |
| Iseki, C | 1 |
| Hamaguchi, Y | 1 |
| Yamamoto, E | 1 |
| Ishizaka, T | 1 |
| Hachino, Y | 1 |
| Wheeler, HE | 1 |
| González-Neira, A | 2 |
| Pita, G | 2 |
| de la Torre-Montero, JC | 2 |
| Alonso, R | 2 |
| Alba, E | 1 |
| Martín, M | 2 |
| Dolan, ME | 1 |
| Yamagiwa, K | 2 |
| Shigematsu, T | 2 |
| Takeda, K | 2 |
| Shirai, M | 2 |
| Amemori, K | 1 |
| Sunda, K | 2 |
| Koike, C | 1 |
| Yamada, T | 1 |
| O'Neil, BH | 1 |
| Cainap, C | 1 |
| Gorbunova, V | 1 |
| Karapetis, CS | 1 |
| Berlin, J | 1 |
| Goldberg, RM | 1 |
| Qin, Q | 1 |
| Qian, J | 1 |
| Ricker, JL | 1 |
| Fischer, J | 1 |
| McKee, MD | 1 |
| Carlson, DM | 1 |
| Kim, TW | 1 |
| Zhao, C | 1 |
| Chen, J | 1 |
| Yu, B | 1 |
| Wu, X | 1 |
| Dai, C | 1 |
| Zhou, C | 1 |
| Chen, X | 1 |
| Park, JS | 1 |
| Jeung, HC | 1 |
| Rha, SY | 1 |
| Ahn, JB | 1 |
| Kang, B | 1 |
| Chon, HJ | 1 |
| Hong, MH | 1 |
| Lim, S | 1 |
| Yang, WI | 1 |
| Nam, CM | 1 |
| Chung, HC | 1 |
| Soveri, LM | 1 |
| Hermunen, K | 1 |
| de Gramont, A | 1 |
| Poussa, T | 1 |
| Quinaux, E | 1 |
| Bono, P | 1 |
| Hamamoto, Y | 1 |
| Yamaguchi, T | 3 |
| Nishina, T | 1 |
| Yamazaki, K | 1 |
| Ura, T | 1 |
| Nakajima, T | 1 |
| Goto, A | 1 |
| Shimada, K | 1 |
| Nakayama, N | 1 |
| Sakamoto, J | 2 |
| Morita, S | 1 |
| Yamada, Y | 1 |
| Meadows, KL | 1 |
| Rushing, C | 1 |
| Honeycutt, W | 1 |
| Latta, K | 1 |
| Howard, L | 1 |
| Arrowood, CA | 1 |
| Niedzwiecki, D | 1 |
| Hurwitz, HI | 1 |
| Müller, V | 1 |
| Fuxius, S | 1 |
| Steffens, CC | 1 |
| Lerchenmüller, C | 1 |
| Luhn, B | 1 |
| Vehling-Kaiser, U | 1 |
| Hurst, U | 1 |
| Hahn, LJ | 1 |
| Soeling, U | 1 |
| Wohlfarth, T | 1 |
| Zaiss, M | 1 |
| Noguchi, Y | 1 |
| Mitani, T | 1 |
| Kawara, H | 1 |
| Tokuyama, Y | 1 |
| Tamura, Y | 1 |
| Uchiyama, K | 1 |
| Shimizu, Y | 1 |
| Martínez, N | 1 |
| Ramos, M | 1 |
| Calvo, L | 1 |
| Lluch, A | 1 |
| Zamora, P | 1 |
| Muñoz, M | 1 |
| Carrasco, E | 1 |
| Caballero, R | 1 |
| García-Sáenz, JÁ | 1 |
| Guerra, E | 1 |
| Caronia, D | 1 |
| Casado, A | 1 |
| Ruíz-Borrego, M | 1 |
| Hernando, B | 1 |
| Chacón, JI | 1 |
| Jimeno, MÁ | 1 |
| Heras, L | 1 |
| De la Haba, J | 1 |
| Constenla, M | 1 |
| Ishii, K | 1 |
| Kanamoto, A | 1 |
| Miyanaga, S | 1 |
| Noto, M | 1 |
| Takeda, T | 1 |
| Tani, T | 1 |
| Yagi, M | 1 |
| Hofheinz, RD | 3 |
| Gencer, D | 2 |
| Schulz, H | 1 |
| Stahl, M | 1 |
| Hegewisch-Becker, S | 1 |
| Loeffler, LM | 1 |
| Kronawitter, U | 1 |
| Bolz, G | 1 |
| Potenberg, J | 1 |
| Tauchert, F | 1 |
| Al-Batran, SE | 1 |
| Schneeweiss, A | 2 |
| Ota, M | 1 |
| Tatsumi, K | 1 |
| Suwa, H | 1 |
| Watanabe, J | 1 |
| Watanabe, K | 1 |
| Osada, S | 1 |
| Tanaka, K | 1 |
| Shoichi, F | 1 |
| Ichikawa, Y | 1 |
| Kunisaki, C | 1 |
| Endo, I | 1 |
| Yokokawa, T | 1 |
| Kawakami, K | 1 |
| Mae, Y | 1 |
| Sugita, K | 1 |
| Watanabe, H | 1 |
| Suzuki, K | 1 |
| Suenaga, M | 1 |
| Mizunuma, N | 1 |
| Hama, T | 1 |
| Matsuda, S | 1 |
| Koketsu, H | 1 |
| Hayakawa, M | 1 |
| Nagata, N | 1 |
| Burkholder, I | 2 |
| Iwase, S | 1 |
| Ishiki, H | 1 |
| Watanabe, A | 1 |
| Shimada, N | 1 |
| Chiba, T | 1 |
| Kinkawa, J | 1 |
| Tojo, A | 1 |
| Carvalho, MD | 1 |
| D'souza, A | 1 |
| Achrekar, MS | 1 |
| Govindarajan, S | 1 |
| Luo, HY | 1 |
| Li, YH | 1 |
| Wang, W | 1 |
| Wang, ZQ | 1 |
| Yuan, X | 1 |
| Ma, D | 1 |
| Wang, FH | 1 |
| Zhang, DS | 1 |
| Lin, DR | 1 |
| Lin, YC | 1 |
| Jia, J | 1 |
| Hu, XH | 1 |
| Peng, JW | 1 |
| Xu, RH | 1 |
| Lee, BN | 1 |
| Jung, S | 1 |
| Darvin, ME | 1 |
| Eucker, J | 1 |
| Kühnhardt, D | 1 |
| Sehouli, J | 1 |
| Chekerov, R | 1 |
| Patzelt, A | 1 |
| Fuss, H | 1 |
| Yu, RX | 1 |
| Lademann, J | 1 |
| Veelenturf, S | 1 |
| Binkhorst, L | 1 |
| Mathijssen, R | 1 |
| Awada, A | 1 |
| Gil, T | 1 |
| Whenham, N | 1 |
| Van Hamme, J | 1 |
| Besse-Hammer, T | 1 |
| Brendel, E | 1 |
| Delesen, H | 1 |
| Joosten, MC | 1 |
| Lathia, CD | 1 |
| Loembé, BA | 1 |
| Piccart-Ghebart, M | 1 |
| Hendlisz, A | 1 |
| Xu, BH | 1 |
| Jiang, ZF | 2 |
| Chua, D | 1 |
| Shao, ZM | 1 |
| Luo, RC | 1 |
| Wang, XJ | 1 |
| Liu, DG | 1 |
| Yeo, W | 1 |
| Yu, SY | 1 |
| Newstat, B | 1 |
| Preston, A | 1 |
| Martin, AM | 1 |
| Chi, HD | 1 |
| Wang, L | 1 |
| Paule, I | 2 |
| Girard, P | 2 |
| Tod, M | 2 |
| Infante, JR | 1 |
| Jones, SF | 1 |
| Bendell, JC | 1 |
| Greco, FA | 1 |
| Yardley, DA | 1 |
| Lane, CM | 1 |
| Spigel, DR | 1 |
| Hainsworth, JD | 1 |
| Burris, HA | 1 |
| Almeida da Cruz, L | 1 |
| Hoff, PM | 1 |
| Ferrari, CL | 1 |
| Riechelmann, RS | 1 |
| Hénin, E | 1 |
| You, B | 1 |
| Freyer, G | 1 |
| Xenidis, N | 1 |
| Chelis, L | 1 |
| Amarantidis, K | 1 |
| Chamalidou, E | 1 |
| Dimopoulos, P | 1 |
| Courcoutsakis, N | 1 |
| Tentes, A | 1 |
| Chiotis, A | 1 |
| Prassopoulos, P | 1 |
| Kakolyris, S | 1 |
| Wang, Z | 1 |
| Lu, J | 1 |
| Leaw, S | 1 |
| Hong, X | 1 |
| Shao, Z | 1 |
| Hu, X | 1 |
| Twelves, C | 1 |
| Scheithauer, W | 1 |
| McKendrick, J | 1 |
| Seitz, JF | 1 |
| Van Hazel, G | 1 |
| Wong, A | 1 |
| Díaz-Rubio, E | 1 |
| Gilberg, F | 1 |
| Cassidy, J | 1 |
| Zhang, RX | 1 |
| Wu, XJ | 1 |
| Wan, DS | 1 |
| Lu, ZH | 1 |
| Kong, LH | 1 |
| Pan, ZZ | 1 |
| Chen, G | 1 |
| Hoesly, FJ | 1 |
| Baker, SG | 1 |
| Gunawardane, ND | 1 |
| Cotliar, JA | 1 |
| Kadoyama, K | 1 |
| Miki, I | 1 |
| Tamura, T | 1 |
| Brown, JB | 1 |
| Sakaeda, T | 1 |
| Okuno, Y | 1 |
| Emi, Y | 1 |
| Kakeji, Y | 1 |
| Oki, E | 1 |
| Saeki, H | 1 |
| Ando, K | 1 |
| Kitazono, M | 1 |
| Sakaguchi, Y | 1 |
| Morita, M | 1 |
| Samura, H | 1 |
| Ogata, Y | 1 |
| Akagi, Y | 1 |
| Natsugoe, S | 1 |
| Shirouzu, K | 1 |
| Tokunaga, S | 1 |
| Sirzen, F | 1 |
| Maehara, Y | 1 |
| Al-Ahwal, MS | 1 |
| Huang, HY | 1 |
| Wang, T | 2 |
| Zhang, SH | 1 |
| Bian, L | 2 |
| Cao, Y | 2 |
| Wu, SK | 1 |
| Song, ST | 1 |
| Agharbi, FZ | 1 |
| Meziane, M | 1 |
| Benhemmne, H | 1 |
| Daoudi, K | 1 |
| Elmesbahi, O | 1 |
| Mikou, O | 1 |
| Mernissi, FZ | 1 |
| Fukuda, M | 1 |
| Yasui, H | 1 |
| Okazaki, S | 1 |
| Kubo, K | 1 |
| Tanaka, M | 1 |
| Une, Y | 1 |
| Setoguchi, Y | 1 |
| Hanada, K | 1 |
| Moriyama, S | 1 |
| Tani, M | 1 |
| Murakami, T | 1 |
| Okuchi, Y | 1 |
| Ogiso, S | 1 |
| Hata, H | 1 |
| Sakata, S | 1 |
| Otani, T | 1 |
| Yamato, T | 1 |
| Ikai, I | 1 |
| Qiao, J | 1 |
| Fang, H | 1 |
| Wiesenthal, A | 1 |
| Matherne, R | 1 |
| Gibson, B | 1 |
| Karachaliou, N | 1 |
| Ziras, N | 1 |
| Syrigos, K | 1 |
| Tryfonidis, K | 1 |
| Papadimitraki, E | 1 |
| Kontopodis, E | 1 |
| Bozionelou, V | 1 |
| Kalykaki, A | 1 |
| Georgoulias, V | 1 |
| Mavroudis, D | 1 |
| Azuma, Y | 1 |
| Hata, K | 1 |
| Sai, K | 1 |
| Udagawa, R | 1 |
| Hirakawa, A | 1 |
| Tohkin, M | 1 |
| Ryushima, Y | 1 |
| Makino, Y | 1 |
| Yokote, N | 1 |
| Morikawa, N | 1 |
| Fujiwara, Y | 1 |
| Saito, Y | 1 |
| Yamamoto, H | 1 |
| Huang, H | 1 |
| Jiang, Z | 1 |
| Wu, S | 1 |
| Song, S | 1 |
| Gafson, AR | 1 |
| Goodkin, O | 1 |
| Begent, R | 1 |
| Corrie, PG | 1 |
| Bulusu, R | 1 |
| Wilson, CB | 1 |
| Armstrong, G | 1 |
| Bond, S | 1 |
| Hardy, R | 1 |
| Lao-Sirieix, S | 1 |
| Parashar, D | 1 |
| Ahmad, A | 1 |
| Daniel, F | 1 |
| Hill, M | 1 |
| Wilson, G | 1 |
| Blesing, C | 1 |
| Moody, AM | 1 |
| McAdam, K | 1 |
| Osborne, M | 1 |
| Gómez-Martin, C | 1 |
| Sánchez, A | 1 |
| Irigoyen, A | 1 |
| Llorente, B | 1 |
| Pérez, B | 1 |
| Serrano, R | 1 |
| Safont, MJ | 1 |
| Falcó, E | 1 |
| Lacasta, A | 1 |
| Reboredo, M | 1 |
| Aparicio, J | 1 |
| Dueñas, R | 1 |
| Muñoz, ML | 1 |
| Regueiro, P | 1 |
| Sanchez-Viñes, E | 1 |
| López, RL | 1 |
| Llambrich, C | 1 |
| Falcou, MC | 1 |
| De Rycke, Y | 1 |
| Cottu, P | 1 |
| Carrié, S | 1 |
| Medjbari, M | 1 |
| Qi, WX | 1 |
| Tang, LN | 1 |
| He, AN | 1 |
| Shen, Z | 1 |
| Yao, Y | 1 |
| Stiefelhagen, P | 1 |
| von Weikersthal, LF | 1 |
| Laubender, RP | 1 |
| Hochhaus, A | 1 |
| Stintzing, S | 1 |
| Blum, JL | 1 |
| Barrios, CH | 1 |
| Feldman, N | 1 |
| Verma, S | 1 |
| McKenna, EF | 1 |
| Lee, LF | 1 |
| Scotto, N | 1 |
| Gralow, J | 1 |
| Chan, HY | 1 |
| Ng, CM | 1 |
| Tiu, SC | 1 |
| Chan, AO | 1 |
| Shek, CC | 1 |
| Amamori, K | 1 |
| Yamanda, T | 1 |
| Taguchi, T | 1 |
| Yamamoto, D | 1 |
| Masuda, N | 1 |
| Oba, K | 1 |
| Nakayama, T | 1 |
| Nagata, T | 1 |
| Nomura, M | 1 |
| Yoshidome, K | 1 |
| Yoshino, H | 1 |
| Matsunami, N | 1 |
| Miyashita, M | 1 |
| Furuya, Y | 1 |
| Ishida, T | 1 |
| Wakita, K | 1 |
| Noguchi, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase 2 Study Of SU011248 Versus Standard-Of-Care For Patients With Previously Treated, Advanced, Triple Receptor Negative (ER, PR, HER2) Breast Cancer[NCT00246571] | Phase 2 | 217 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| An Open Label, Pilot Study Evaluating the Effect of Topical Sildenafil as Pre-Treatment for Hand-Foot Skin Reaction[NCT03229512] | Early Phase 1 | 2 participants (Actual) | Interventional | 2017-04-11 | Completed | ||
| Randomized Phase II Trial of Continuous Versus Standard Capecitabine in Advanced Breast Cancer.[NCT00418028] | Phase 2/Phase 3 | 195 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E[NCT05939726] | 90 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | |||
| A Randomized, Open-label Phase III Trial of Mapisal® Versus an Urea Hand-foot Cream as Prophylaxis for Capecitabine-induced Hand-foot Syndrome in Patients With Gastrointestinal Tumors or Breast Cancer[NCT01626781] | 0 participants | Expanded Access | No longer available | ||||
| Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246] | Phase 2 | 66 participants (Anticipated) | Interventional | 2022-12-08 | Active, not recruiting | ||
| Maintenance Treatment With Capecitabine Versus Observation After First Line Chemotherapy in Patients With Metastatic Colorectal Cancer: a Randomized Phase II Study[NCT02027363] | Phase 2 | 245 participants (Anticipated) | Interventional | 2010-01-31 | Active, not recruiting | ||
| Capecitabine Metronomic Chemotherapy Versus Conventional Chemotherapy as Maintenance Treatment in Metastatic Colorectal Cancer[NCT02893540] | Phase 2/Phase 3 | 250 participants (Anticipated) | Interventional | 2016-09-30 | Recruiting | ||
| Maintenance Treatment With S-1 Versus Observation After First-line Chemotherapy in Patients With Advanced Gastric Cancer: a Randomized Phase II Study[NCT03701373] | Phase 2 | 200 participants (Anticipated) | Interventional | 2016-01-01 | Recruiting | ||
| An Open-Label Multicenter Study Administering Lapatinib and Capecitabine (Xeloda) in Women With Advanced or Metastatic Breast Cancer[NCT00508274] | Phase 3 | 52 participants (Actual) | Interventional | 2007-07-18 | Terminated (stopped due to Primary analysis was completed in 2015 and data collection post 1-Jul-2019 was not reportable due to local regulations in China.) | ||
| Phase II Study of an All-Oral Combination of Capecitabine (X) and Cyclophosphamide (C) in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer[NCT00589901] | Phase 2 | 60 participants (Anticipated) | Interventional | 2006-08-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Time in months from the date of randomization to date of death due to any cause. OS was calculated as (date of death minus randomization date plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death). (NCT00246571)
Timeframe: Baseline until death (up to 3 years after first dose of study medication)
| Intervention | months (Median) |
|---|---|
| Sunitinib | 9.4 |
| Standard of Care | 10.5 |
Probability that the participants will survive at end of 1 year from the first dose of study treatment. Calculated using data collected from baseline until death (up to 3 years after first dose of study medication). Probability calculated from Kaplan-Meier estimate. (NCT00246571)
Timeframe: Baseline until death (up to 3 years after first dose of study medication)
| Intervention | ratio (Number) |
|---|---|
| Sunitinib | 0.376 |
| Standard of Care | 0.446 |
Blood samples were collected to enumerate the number of total CECs and sVEGFR1, sVEGFR2 and sVEGFR3 protein expression and/or cellular viability. (NCT00246571)
Timeframe: Days 1 and 15 of Cycles 1, 2 and 3, Day 1 of Cycles 4 and 5, and every odd cycle thereafter, and EOT/withdrawal
| Intervention | cells/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=42, 48) | Cycle 1, Day 15 (n=28, 37) | Cycle 2, Day 1 (n=33, 35) | Cycle 2, Day 15 (n=7, 5) | Cycle 3, Day 1 (n=27, 25) | Cycle 3, Day 15 (n=4, 1) | Cycle 4, Day 1 (n=3, 5) | Cycle 5, Day 1 (n=2, 2) | EOT (n=18, 18) | |
| Standard of Care | 1176.92 | 1199.32 | 1048.31 | 852.96 | 509.75 | 231.80 | 976.79 | 2031.67 | 1087.94 |
| Sunitinib | 944.67 | 630 | 512.39 | 1310.86 | 390.09 | 923.85 | 169.24 | 145.68 | 477.83 |
Blood samples were collected to enumerate the number of total CTCs and insulin growth factor 1R positive (IGF-1R+) CTCs (NCT00246571)
Timeframe: Days 1 and 15 of Cycles 1, 2 and 3, Day 1 of Cycles 4 and 5, and every odd cycle thereafter, and EOT/withdrawal
| Intervention | cells/7.5 mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=33, 28) | Cycle 1, Day 15 (n=20, 16) | Cycle 2, Day 1 (n=19, 17) | Cycle 2, Day 15 (n=3, 7) | Cycle 3, Day 1 (n=8, 15) | Cycle 3, Day 15 (n=2, 4) | Cycle 4, Day 1 (n=2, 5) | Cycle 5, Day 1 (n=2, 3) | EOT (n=17,4) | |
| Standard of Care | 17.71 | 10.69 | 3.18 | 0.86 | 10.60 | 0 | 0.60 | 0.33 | 3 |
| Sunitinib | 119.76 | 183.60 | 189 | 33.33 | 36.50 | 40.50 | 61 | 19.50 | 55 |
(NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=54) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | 0.02 | 29.4 | 32.3 | 33.4 | 28.5 | 40.4 | 30.9 | 36.1 | 21.3 |
(NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=54) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | 0.14 | 94.9 | 94.4 | 91.6 | 78.6 | 105 | 82.2 | 84.2 | 63.6 |
Ctrough = plasma concentration of SU012662 prior to study drug administration, dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol. (NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=ND) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | NA | 29.9 | 37.2 | 37.3 | 39.8 | 40.1 | 38.7 | 41.9 | 28.6 |
Ctrough = plasma concentration of sunitinib prior to study drug administration, dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol. (NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=ND) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | NA | 67.5 | 73.4 | 69.8 | 69.3 | 65.3 | 68.7 | 58.4 | 64.0 |
Ctrough = plasma concentration of total drug (Sunitinib + SU012662) prior to study drug administration dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol. (NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=ND) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | NA | 97.4 | 111 | 107 | 109 | 105 | 107 | 100 | 92.5 |
Time in months from the first documentation of objective tumor response (CR or PR) to objective tumor progression or death. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response. (NCT00246571)
Timeframe: Time from first response to disease progression up to 3 years from first dose
| Intervention | months (Median) | |
|---|---|---|
| Core radiology assessment (n=3,7) | Investigator's assessment (n=10,12) | |
| Standard of Care | NA | 4.6 |
| Sunitinib | 3.0 | 3.6 |
(NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=54) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | 0.12 | 65.53 | 62.09 | 58.20 | 50.03 | 64.61 | 51.25 | 48.07 | 42.23 |
Plasma concentrations of sKIT were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5 and 7), and EOT/withdrawal
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=83, 64) | Cycle 2 Day 1 (n=66, 48) | Cycle 3 Day 1 (n=49, 35) | Cycle 4 Day 1 (n=33, 27) | Cycle 5 Day 1 (n=28, 19) | Cycle 7 Day 1 (n=9, 8) | End Of Treatment (n=49, 11) | |
| Standard of Care | 62232.81 | 65843.75 | 63582.86 | 62885.19 | 54811.05 | 56237.50 | 72854.55 |
| Sunitinib | 61862.65 | 44987.88 | 30855.10 | 25887.88 | 21696.07 | 18166.67 | 25004.08 |
Plasma concentrations of sPlGF were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5 and 7), and EOT/withdrawal
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=15, 11) | Cycle 2 Day 1 (n=11, 9) | Cycle 3 Day 1 (n=5, 4) | Cycle 4 Day 1 (n=2, 3) | Cycle 5 Day 1 (n=1, 3) | Cycle 7 Day 1 (n=1, 1) | End Of Treatment (n=5, 0) | |
| Standard of Care | 37.23 | 36.24 | 40.08 | 33.23 | 51.83 | 38.50 | 0 |
| Sunitinib | 36.96 | 168.05 | 72.16 | 144.60 | 118.30 | 176.60 | 87.54 |
Plasma concentrations of sVEGF-A were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5, and 7), and EOT/withdrawal
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=83, 66) | Cycle 2 Day 1 (n=67, 50) | Cycle 3 Day 1 (n=49, 37) | Cycle 4 Day 1 (n=33, 28) | Cycle 5 Day 1 (n=28, 20) | Cycle 7 Day 1 (n=9, 10) | End Of Treatment (n=49, 12) | |
| Standard of Care | 151.49 | 170.43 | 129.31 | 129.88 | 126.97 | 115.58 | 94.76 |
| Sunitinib | 152.28 | 455.17 | 265.56 | 274.94 | 324.09 | 241.78 | 294.66 |
Plasma concentrations of sVEGFR3 were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5, and 7), and EOT/withdrawal
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=83, 64) | Cycle 2 Day 1 (n=66, 48) | Cycle 3 Day 1 (n=48, 35) | Cycle 4 Day 1 (n=32, 27) | Cycle 5 Day 1 (n=28, 20) | Cycle 7 Day 1 (n=9, 9) | End Of Treatment (n=48, 10) | |
| Standard of Care | 25857.19 | 24515.83 | 29034.86 | 27929.63 | 32949 | 32004.44 | 29194 |
| Sunitinib | 24124.82 | 16299.70 | 14459.38 | 13702.81 | 16345.36 | 24795.56 | 26746.46 |
"Time in months from start of study treatment to first documentation of objective tumor progression (per RECIST) or death due to any cause. PFS was calculated as (first event date minus first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was Death)." (NCT00246571)
Timeframe: Baseline, every 6 weeks until disease progression or death (up to 3 years from first dose)
| Intervention | Months (Median) | |
|---|---|---|
| Core radiology laboratory assessment | Investigator's assessment | |
| Standard of Care | 2.7 | 2.5 |
| Sunitinib | 2.0 | 1.7 |
Objective response based assessment of confirmed response (CR) or confirmed partial response (PR) according to RECIST. CR are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. PR are those with a greater than or equal to (≥) 30% decrease in the sum of the longest dimensions (SLD) of the target lesions taking as a reference the baseline SLD. (NCT00246571)
Timeframe: Baseline until response or disease progression (up to 3 years from first dose)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Core radiology laboratory assessment | Investigator's assessment | |
| Standard of Care | 6.7 | 11.5 |
| Sunitinib | 2.7 | 8.8 |
"A patient experiences a Clinical Benefit if the following is satisfied:~Criterion: The patient has Complete response, Partial Response or Stable Disease and it continues during more than 3 months." (NCT00418028)
Timeframe: "Months from CR,PR or SD (the first one) until Progression date, new treatment or last contact date."
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Cint) | 56 |
| Arm B (Ccont) | 56 |
An event is defined as death. A patient is censored if she does not die. The censoring date is last contact date. (NCT00418028)
Timeframe: Time to survival is the number of months from the study treatment start date to the date of death, assessed up to 100 months.
| Intervention | Months (Median) |
|---|---|
| Arm A (Cint) | 27.34 |
| Arm B (Ccont) | 24.11 |
Progression Free Survival is defined as the time (in months) from the moment the patient starts the study treatment to the date of progressive disease. That is, a patient has an event is she progresses or dies for any reason. (NCT00418028)
Timeframe: Time (in months) from the moment the patient starts the study treatment to the date of progressive disease assessed up to 84 months.
| Intervention | Months (Median) |
|---|---|
| Arm A (Cint) | 8.52 |
| Arm B (Ccont) | 6.84 |
"Response duration is computed for all patients with Partial Response or Complete Response, during the treatment period, as the time from the moment the Partial or Complete Response is reported to the date the patient Progresses or Dies, whichever happens first.~A patient is censored if she does not progress or die. In these cases Response duration is computed as the time from the moment the Partial or Complete Response is reported to the last contact date." (NCT00418028)
Timeframe: Time from the moment the Partial or Complete Response is reported to the date the patient Progresses or Dies, whichever happens first, assessed up to 72 weeks.
| Intervention | Months (Median) |
|---|---|
| Arm A (Cint) | 10.07 |
| Arm B (Ccont) | 7.20 |
Response was evaluated using the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), every 3 cycles of chemotherapy (each cycle lasts 3 weeks) and at the end of treatment (at 21 weeks from the start of treatment). (NCT00418028)
Timeframe: Through the study treatment, an average of 5 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Cint) | 30 |
| Arm B (Ccont) | 31 |
Time to Progression (TTP) is defined as the time (in months) from the moment the patient starts the study treatment to the date of progressive disease. That is, a patient has an event is she progresses or dies due to progressive disease. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0). (NCT00418028)
Timeframe: After 1 year from the treatment start day.
| Intervention | months (Median) |
|---|---|
| Arm A (Cint) | 8.68 |
| Arm B (Ccont) | 6.84 |
"Time to treatment failure (TTF) is defined as the time (in months) from the moment the patient starts the study treatment to the end of treatment date (due to death, progressive disease, adverse events, patient's decision or investigator criteria.~If a patient did not end the treatment, it is censored. The censoring date is the date of the last dose received." (NCT00418028)
Timeframe: Time (in months) from the moment the patient starts the study treatment to the end of treatment date (due to death, progressive disease, adverse events, patient's decision or investigator criteria, assessed up to 72 months.
| Intervention | Months (Median) |
|---|---|
| Arm A (Cint) | 5.41 |
| Arm B (Ccont) | 5.87 |
"CBR is defined by the percentage of participants achieving either a confirmed tumor response of complete response (CR) or partial response (PR) or stable disease (SD) for at least 24 weeks. Response Criteria in Solid Tumors (RECIST) is a system for measuring tumor shrinkage or progression in terms of the longest dimensions of the tumor on imaging scans such as computerized tomography (CT). A partial response requires a decrease of 30% or more, complete response requires all target lesions disappear, Progression requires an increase of at least 20%, and Stable disease falls in between these two. All responses have a repeat assessment to confirm the response." (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was approx. 90 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Lapatinib + Capecitabine | 57.7 |
Duration of response (complete response, partial response or stable disease) is defined as the time of first documentation of disease response until the date of disease progression or death due to breast cancer, whichever occurs first. DOR only applied to participants for whom best overall response was complete response (CR), partial response (PR) or stable disease (SD). Participants who had not had a partial response, complete response or stable disease at the cut-off date for this endpoint analysis were censored for duration of response. (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 88.80 months.
| Intervention | Months (Median) |
|---|---|
| Lapatinib + Capecitabine | 8.18 |
PFS is defined as the time from first dose date until the date of disease progression or death due to any reason, whichever occurs first. (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 90.38 months.
| Intervention | Months (Median) |
|---|---|
| Lapatinib + Capecitabine | 6.34 |
Six Months Progression-Free Survival is defined as the percentage of surviving participants who are progression-free longer than six months (greather than 180 days) after the first start date of study treatment. (NCT00508274)
Timeframe: at Baseline and every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed up to 90.38 months, with 6 months PFS reported.
| Intervention | Percentage of participants (Number) |
|---|---|
| Lapatinib + Capecitabine | 53.55 |
Time to response is defined as the time from first dose date until first documentation of disease response. TTR only applied to participants for whom best overall response was complete response (CR), partial response (PR) or stable disease (SD). Participants who had not had a partial response, complete response or stable disease at the cut-off date for this endpoint analysis were censored for time to response. (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was approx. 14.78 months
| Intervention | Months (Median) |
|---|---|
| Lapatinib + Capecitabine | 4.07 |
On treatment deaths were collected from the start of treatment up to 30 days after study drug discontinuation, for a maximum duration of 4276 days (treatment duration ranged from 13 - 4246 days) for Lapatinib and 3384 days (treatment duration ranged form 8 - 3354 days) for Capecitabine. Total deaths was collected from study start to study end (LPLV). (NCT00508274)
Timeframe: up to 4276 days for Lapatinib/up to 3384 days for Capecitabine (on-treatment), approx. 12 years (all collected deaths)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Total Deaths | On-treatment Deaths | |
| Lapatinib + Capecitabine | 11 | 2 |
Number of participants who had Central Nervous System metastasis as the first site of relapse. CT, Magnetic Resonance Imaging, etc. were used for the assessment. (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 90 months
| Intervention | participants (Number) | |
|---|---|---|
| Participants with any site of relapse | Participants with CNS disease as first site of relapse | |
| Lapatinib + Capecitabine | 17 | 2 |
8 reviews available for fluorouracil and Hand-Foot Syndrome
| Article | Year |
|---|---|
Capecitabine induced fingerprint loss: Case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Fluorouracil | 2022 |
Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Fluorouracil; Hand-Foot Syndrome; Humans; Hydro-Lyase | 2020 |
Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis.
Topics: Administration, Oral; Antineoplastic Agents; Colorectal Neoplasms; Databases, Bibliographic; Disease | 2018 |
Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2018 |
Unilateral hand-foot syndrome: does it take sides? Case report and literature review.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Ha | 2012 |
Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Bacteremia; Breast Neoplasms; Capecitabine; Deoxycytidine; Fatal Ou | 2011 |
Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protoco | 2013 |
Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Breast Neoplasms, | 2012 |
32 trials available for fluorouracil and Hand-Foot Syndrome
| Article | Year |
|---|---|
Effect of a Novel Soaking Solution Used in Patients With Hand-Foot Syndrome as a Result of Capecitabine Treatment: A Randomized and Self-Controlled Trial.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Female; Fluorouracil; Hand-Foot Syn | 2022 |
Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC s
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trial | 2022 |
Effect of a Structured Teaching Module Including Intensive Prophylactic Measures on Reducing the Incidence of Capecitabine-Induced Hand-Foot Syndrome: Results of a Prospective Randomized Phase III Study.
Topics: Capecitabine; Fluorouracil; Hand-Foot Syndrome; Humans; Incidence; Prospective Studies; Quality of L | 2020 |
Efficacy of topical
Topics: Administration, Cutaneous; Adult; Aged; Double-Blind Method; Female; Fluorouracil; Hand-Foot Syndrom | 2021 |
Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; | 2018 |
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brea | 2013 |
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, A | 2013 |
Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Agents; Body Mass Index; Breast | 2014 |
Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
Effect of modified taohongsiwu decoction on patients with chemotherapy-induced hand-foot syndrome.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dr | 2014 |
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 2014 |
Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2014 |
A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2014 |
Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Double-Blind Method; Female; Fluoro | 2015 |
Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Capecitabine; Disease-Free Survival; Drug Administ | 2015 |
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Antioxidants; Breast Neopla | 2015 |
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Antioxidants; Breast Neopla | 2015 |
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Antioxidants; Breast Neopla | 2015 |
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Antioxidants; Breast Neopla | 2015 |
The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2014 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2016 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2016 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2016 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2016 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2016 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2016 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2016 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2016 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2016 |
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2011 |
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Capecit | 2011 |
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Be | 2012 |
Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2012 |
An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anorexia; Anthracyclines; Antineoplastic Combined Chemotherapy Pr | 2012 |
Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2012 |
Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.
Topics: Adenocarcinoma; Aged; Algorithms; Antimetabolites, Antineoplastic; Capecitabine; Celecoxib; Colorect | 2012 |
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridg | 2012 |
Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2012 |
A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diseas | 2012 |
Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2012 |
Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Surv | 2012 |
Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2013 |
46 other studies available for fluorouracil and Hand-Foot Syndrome
| Article | Year |
|---|---|
Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer.
Topics: Capecitabine; Cardiotoxicity; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Hand-Foot Syndr | 2022 |
Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Ne | 2022 |
Capecitabine and Hand-foot Syndrome: A Case Report.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndro | 2023 |
Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of patient-reported outcomes.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Drug-R | 2022 |
Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil.
Topics: Animals; Capecitabine; Deoxycytidine; Fluorouracil; Hand-Foot Syndrome; Mice; Pyroptosis; Quality of | 2023 |
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Fluorouracil; Hand-Foot Syndrome; Humans; Pharmacogen | 2023 |
Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer.
Topics: Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Hand-Foot Syndrome; Humans; Imm | 2023 |
Apatinib-induced Grade 3 hand-foot syndrome in advanced lung adenocarcinoma successful treated with thalidomide: A case report.
Topics: Adenocarcinoma of Lung; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Lung Neoplasms; Pyridines; | 2020 |
Tegafur/gimeracil/oteracil (TS-1)-induced erythroderma with an extensive mucosal involvement and hand-foot syndrome.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neop | 2017 |
TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.
Topics: Adult; Antimetabolites, Antineoplastic; Breast; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, B | 2018 |
Chemotherapy-induced erythrodysesthesia of the breast.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neopla | 2018 |
Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc | 2013 |
Comparative assessment of skin and subcutaneous toxicity in patients of advanced colorectal carcinoma treated with different schedules of FOLFOX.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2013 |
Using continuous data on tumour measurements to improve inference in phase II cancer studies.
Topics: Antineoplastic Agents; Capecitabine; Clinical Trials, Phase II as Topic; Computer Simulation; Data I | 2013 |
[A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Topical henna ameliorated capecitabine-induced hand-foot syndrome.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; | 2014 |
[Efficacy of AboundTM for hand-foot syndrome caused by capecitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Arginine; Butyrates; Capecitabine; Deoxycytidine; Female; Flu | 2013 |
Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses.
Topics: Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Femal | 2014 |
[Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine | 2013 |
Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance study.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2014 |
[A case of lacrimal duct obstruction caused by capecitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine | 2015 |
[The present status of CapeOX as adjuvant chemotherapy for colorectal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, | 2015 |
Images in clinical medicine. Loss of fingerprints.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dermatoglyphic | 2015 |
Risk Factors Exacerbating Hand-Foot Skin Reaction Induced by Capecitabine plus Oxaliplatin with or without Bevacizumab Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecit | 2015 |
Unilateral Capecitabine-related Hand-foot Syndrome.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colon | 2015 |
Reply to S. Iwase et al.
Topics: Antimetabolites, Antineoplastic; Antioxidants; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndro | 2016 |
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome.
Topics: Antimetabolites, Antineoplastic; Antioxidants; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndro | 2016 |
Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidin | 2016 |
Influence of Chemotherapy on the Antioxidant Status of Human Skin.
Topics: Adult; Aged; Antineoplastic Agents; Antioxidants; Carotenoids; Docetaxel; Doxorubicin; Female; Fluor | 2016 |
Capecitabine and the Risk of Fingerprint Loss.
Topics: Capecitabine; Carcinoma, Hepatocellular; Colorectal Neoplasms; Dermatoglyphics; Female; Fluorouracil | 2017 |
Empirical Bayes estimation of random effects of a mixed-effects proportional odds Markov model for ordinal data.
Topics: Antineoplastic Agents; Bayes Theorem; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Empirical R | 2011 |
Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation.
Topics: Adaptation, Physiological; Algorithms; Antimetabolites, Antineoplastic; Bayes Theorem; Capecitabine; | 2012 |
Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.
Topics: Adverse Drug Reaction Reporting Systems; Capecitabine; Data Mining; Deoxycytidine; Diarrhea; Fluorou | 2012 |
Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidi | 2013 |
Chemotherapy and fingerprint loss: beyond cosmetic.
Topics: Capecitabine; Deoxycytidine; Dermatoglyphics; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle | 2012 |
[Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].
Topics: Adult; Agranulocytosis; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 2011 |
[Capecitabine-induced hyperpigmentation followed by hand-foot syndrome: a new case report].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Follo | 2012 |
[Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2012 |
Hand-foot syndrome related to chemotherapy.
Topics: Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans | 2012 |
Capecitabine-induced systemic lupus erythematosus and palmoplantar erythrodysesthesia.
Topics: Capecitabine; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Lupus Erythematosus, | 2012 |
Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Confidence | 2012 |
Observations and hypothesis on an individual patient topically treated for capecitabine-induced Palmar-Plantar syndrome.
Topics: 2-Propanol; Acetates; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Camphor; Capecita | 2010 |
[Breast cancer and the hand-foot syndrome].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deo | 2012 |
[Therapy traces on hands and feet in a patient with colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diagnosis, Di | 2012 |
Hypertriglyceridaemia-induced pancreatitis: a contributory role of capecitabine?
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxy | 2012 |
[Assessment of hand-foot syndrome in cancer outpatients undergoing chemotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; F | 2012 |